Last reviewed · How we verify
Atazanavir (Reyataz)
Atazanavir inhibits HIV protease, preventing the cleavage of viral polyproteins and blocking the maturation of infectious HIV particles.
Atazanavir inhibits HIV protease, preventing the cleavage of viral polyproteins and blocking the maturation of infectious HIV particles. Used for HIV-1 infection in treatment-naïve and treatment-experienced patients (as part of combination antiretroviral therapy).
At a glance
| Generic name | Atazanavir (Reyataz) |
|---|---|
| Sponsor | Germans Trias i Pujol Hospital |
| Drug class | HIV protease inhibitor |
| Target | HIV protease |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Atazanavir is a protease inhibitor that binds to the active site of HIV protease, an enzyme essential for processing viral precursor proteins into functional components. By blocking this enzymatic activity, the drug prevents the formation of mature, infectious viral particles, thereby reducing viral replication and slowing disease progression. It is typically used as part of combination antiretroviral therapy (cART) in HIV-infected patients.
Approved indications
- HIV-1 infection in treatment-naïve and treatment-experienced patients (as part of combination antiretroviral therapy)
Common side effects
- Hyperbilirubinemia (unconjugated)
- Jaundice
- Nausea
- Diarrhea
- Headache
- Rash
- Nephrolithiasis
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults (PHASE3)
- Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (PHASE3)
- Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum
- Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (PHASE2, PHASE3)
- Population Pharmacokinetics of Antiretroviral in Children
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Atazanavir (Reyataz) CI brief — competitive landscape report
- Atazanavir (Reyataz) updates RSS · CI watch RSS
- Germans Trias i Pujol Hospital portfolio CI